Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC

Big Data Research Platform Aggregates, Interprets Molecular, Life Sciences Data

By BiotechDaily International staff writers
Posted on 29 Jul 2013
A new research platform’s Big Data technology enables users to apply genomic data from disparate sources in innovative and helpful ways across life sciences research.

Boehringer Ingelheim (Ingelheim, Germany) has signed a multiyear renewal agreement to the NextBio research platform (Santa Clara, CA, USA). The new agreement also extends the user base for NextBio across Boehringer Ingelheim’s global research organization.

“Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies and has been a user of NextBio Research for the past year,” said Saeid Akhtari, NextBio president and chief executive officer. “This expanded license and broadened access to the NextBio Research platform is a strong endorsement of our technology’s value for enabling life scientists to quickly examine and understand their data in the context of published research worldwide.

“NextBio Research provides a comprehensive platform for exploratory, preclinical and early translational research in drug discovery and biotechnology research,” Mr. Akhtari added. “Integrating proprietary analysis results with extensive curated content, NextBio enhances researchers’ ability to design experiments, test hypotheses, and validate results, leading to better target analysis, understanding of disease mechanisms, and analysis of results across species.”

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. It operates globally with 140 affiliates and more than 46,000 employees. The company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine. In 2012, Boehringer Ingelheim achieved net sales of about EUR 14.7 billion. R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.

NextBio provides a cutting-edge scientific platform to aggregate and interpret large quantities of molecular and other life sciences data for research and clinical applications. NextBio’s platform integrates data from multiple repositories and diverse technologies by way of a unique correlation engine, which precomputes billions of significant connections between disparate public and proprietary clinical and research data. This feature enables interpretation of an individual’s molecular data.

Furthermore, the platform provides translational researchers with the capability to gaze across the clinical and molecular data of entire populations for clinical trial stratification and selection, hypotheses generation, and biomarker discovery. NextBio Clinical, which recently passed an independent HIPAA audit, is designed for seamless integration with existing clinical and research systems. Backed by highly scalable, Big Data technology, it is capable of analyzing petabytes of data. NextBio’s platform is delivered as a software as a service (SaaS) system, resulting in fast deployment and rapid return on investment.

NextBio is currently used by researchers and clinicians in over 50 top commercial and academic institutions.

Related Links:

Boehringer Ingelheim
NextBio



Channels

Genomics/Proteomics

view channel
Image: Researchers have generated disease-free stem cells from patients with mitochondrial disease that can be converted into any cell type including neuronal progenitors (left) or heart cells (right). These could potentially be used for future transplantation into patients (Photo courtesy of Salk Institute of Biological Studies).

Methods Developed to Generate Normal Stem Cells from Patients with Mitochondrial Defects

A recent paper described two methods for converting cells from patients with mitochondrial defects into normal pluripotent stem cells that could be induced to differentiate into several different types of tissues.... Read more

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Lab Technologies

view channel
Image: The Leica DM2500 LED Microscope for clinical laboratories and research applications (Photo courtesy of Leica Microsystems).

New LED Microscope Completes Line of Clinical and Research Tools

A popular microscope used for both clinical and research applications is now available with LED illumination. The Leica (Wetzlar, Germany) DM2500 and DM2500 LED microscopes represent a class of tools... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.